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Abstract 
Background: Retinal vessel calibre and vascular dilation/constriction in response to flicker light provocation may 
provide a measure distinguishing patients suffering from diabetes mellitus and/or cardiovascular disease.
Methods: One hundred and sixteen age and sex matched patients with diabetes mellitus (DM), cardiovascular dis-
ease (CVD) and both DM and CVD (DM + CVD) underwent systemic and intraocular pressure measurements. Retinal 
vessel calibres were assessed using a validated computer-based program to compute central retinal artery and vein 
equivalents (CRVE) from monochromatic retinal images. Vessel dilation and constriction responses to flicker light 
provocation were assessed by continuous retinal vessel diameter recordings. Plasma endothelial markers von Wille-
brand factor (vWf ) and soluble E selectin (sEsel) were measured by ELISA.
Results: Retinal vessel calibres were comparable across groups but CRVE correlated significantly with disease dura-
tion in DM patients (r = 0.57, p < 0.001). Patients suffering DM only exhibited reduced arterial vasomotion at rest 
and reduced arterial constriction following flicker light induced vessel dilation compared to patients with CVD and 
those suffering both CVD + DM (p = 0.030). Patients suffering from CVD + DM exhibited significant differences 
between each flicker cycle in regards to arterial maximum constriction (p = 0.006) and time needed to reach arterial 
maximum dilation (p = 0.004), whereas the other two groups did not show such inconsistencies between individual 
flicker cycles. vWf was raised in CVD + DM compared to the other two groups (p ≤ 0.02), whilst sEsel was raised in 
CVD + DM compared to DM alone (p = 0.044).
Conclusions: Dynamic retinal vascular calibres as obtained by continuous diameter measurements using flicker light 
provocation can reveal subtle differences between groups suffering from CVD with and without DM. This difference in 
reaction pattern and lack of arterial constriction in DM may provide a suitable marker to monitor progression.
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Background
Cardiovascular disease (CVD) has a complex pathogen-
esis and can manifest as coronary artery disease (such 
as previous myocardial infarction and coronary artery 
stenosis/occlusion) cerebrovascular disease (leading 
to stroke) and peripheral artery disease (often requir-
ing amputation). Diabetes mellitus (DM) is a major risk 
factor for CVD, but many diabetics also have other risk 
factors such as hypertension, and suffer from microvas-
cular disease, such as of the retinal vessels, causing retin-
opathy [1, 2]. Leading clinical aspects of retinal vascular 
disease are disease duration and the degree of hypergly-
caemia (as assessed by glycated haemoglobin  [HbA1c]), 
and accordingly the accurate assessment of retinal func-
tion is a highly-sought after clinical tool [3, 4].
The retinal vasculature is readily accessible and can be 
observed non-invasively by fundus photography, video 
recording and tomographic technology. It’s potential 
as screening tool for cerebrovascular [5] and cardiovas-
cular disease [6, 7] has been supported through large 
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population studies [8–11]. These studies demonstrated 
a relationship between retinal vessel calibres and cardio-
vascular risk [11, 12]. Individuals with good cardiovascu-
lar health are less likely to have signs of retinopathy such 
as dilated retinal venules and narrow retinal arterioles, 
both of which are associated with increased risk of stroke 
and coronary artery disease [13].
While retinal vessel calibres provide only static indi-
ces, dynamic measurements such as retinal vessel 
reactivity to flicker light provocation can provide fur-
ther insight into the status of the retinal microcircula-
tion. Several authors have demonstrated a link between 
measures of cardiovascular health and retinal vessel 
dynamics, such as a decrease in retinal vessel dilation 
in presence of decreased flow mediated dilation of the 
brachial artery [14], prolonged reaction times in retinal 
arterial responses to flicker light in patients suffering 
from coronary artery disease [15], and decreased vessel 
dilation to flicker light in patients with coronary artery 
disease, and which depends on the severity of the disease 
[16]. Previous research has shown reduced retinal ves-
sel dilation to flicker light in DM patients compared to 
controls which further reduced with the severity of dia-
betic retinopathy [17–19]. This lack of reactive hyper-
aemia in DM patients has been attributed to abnormal 
glial regulation of the retinal vasculature [20] as well as 
endothelial cell dysfunction leading to reduced nitric 
oxide (NO) synthase and sensitivity [17, 21]. While most 
studies conducted in DM patients examined both arter-
ies and venous responses, they have not evaluated the full 
response to flicker light which includes the vasomotion at 
rest, vasoconstriction post flicker and reaction time.
Whilst retinal vessel dynamics have the potential as 
tool for risk stratification and screening as evidenced by 
the progressively decreasing vessel dilation with increas-
ing severity of diabetic retinopathy, the relative influence 
of how different pathological combinations and risk fac-
tors impact on retinal vessel parameters is unclear. We 
hypothesised that retinal vessel responses to flicker light 
would be more adverse in those patients with both DM 
and CVD compared to patients with either DM or CVD 
alone.
Methods
The study was approved by the National Health Service 
Research Ethics Committee East Midlands-Leicester 
(Ref: 12/EM/0062) and the Aston University Ethics 
Committee and adhered to the Declaration of Helsinki. 
Patients were recruited from the cardiovascular rehabili-
tation unit, hypertensive and diabetic outpatient clinics at 
City Hospital (Birmingham, UK). All patients gave writ-
ten informed consent. Three groups were defined prior 
to recruitment: patients suffering from diabetes mellitus 
(type 1 and type 2) but free from cardiovascular: patients 
suffering from cardiovascular disease but free from dia-
betes, and patients suffering from both diabetes and car-
diovascular disease. Diabetes was defined by attendance 
at a diabetes clinic and  HbA1c  >  50  mmol/mol (6.7%). 
Cardiovascular disease was defined as history of myocar-
dial infarction, coronary artery stenosis/occlusion, coro-
nary artery bypass grafting, stroke, iliac/femoral artery 
stenosis or bypass or lower limb/foot/toe amputation. 
Exclusion criteria included recent (<3 month) myocardial 
infarction, stroke, or surgery, cancer, autoimmune dis-
ease (such as rheumatoid arthritis) or ophthalmological 
disease such as age-related macular degeneration. Serum 
endothelial markers von Willebrand factor (vWf) and 
soluble E selectin (sEsel) were measured by commercial 
ELISA (Dako, Ely, UK and R & D Systems, Abingdon, 
UK). Clinical, laboratory, medication and demographic 
data were collected and are shown in Table 1.
Patients were advised to abstain from caffeinated drinks 
for a minimum of 12 h prior to their ocular examination. 
All patients were seated in a temperature-controlled 
room (21 ± 2 °C) for a minimum of 15–20 min to achieve 
a stable blood pressure (systolic blood pressure [SBP] and 
diastolic blood pressure [DBP] were measured using a 
digital sphygmomanometer [UA767, PMS Instruments, 
UK]). Intraocular pressure (IOP) was measured using a 
rebound t tonometer (I-Care, Mainline Instruments Ltd., 
UK) after which pupils were dilated with 1% tropicamide 
(Chauvin Pharmaceuticals Ltd., Kingston-Upon-Thames, 
UK).
Dynamic and static retinal vessel assessment
Once pupils were fully dilated, digital fundus images 
and reactivity parameters of retinal arteries and veins to 
flicker light provocation were obtained from one eye of 
each patient [58 right eyes and 58 left eyes] (Retinal ves-
sel analyser [RVA], Imedos Systems [UG] haftungsbe-
schraenkt Jena, Germany) [22]. For static vessel analysis 
monochromatic (red-free) fundus images were obtained, 
at a 30 °C camera angle with the optic nerve head (ONH) 
centred, using the inbuilt Zeiss FF450 +  fundus camera 
(Zeiss GmbH, Germany), see Fig. 1. Summarised retinal 
vessel calibres of retinal arteries (central retinal artery 
equivalent, CRAE), veins (central retinal vein equivalent, 
CRVE) and the retinal artery-to-vein ratio (AVR) were 
calculated according to a standard protocol [23].
Dynamic imaging was followed by static imaging. Reti-
nal vessel diameters were measured continuously at a 
sampling rate of 25 Hz. Stimulation of retinal blood ves-
sels was done by optoelectronic interruption of the green 
fundus illumination used by the RVA resulting in a flicker 
light provocation with a 12.5 Hz frequency [24–26]. After 
BP stabilisation and image focussing one vessel segment 
Page 3 of 10Heitmar et al. Cardiovasc Diabetol  (2017) 16:56 
of each, the superior temporal retinal artery and vein was 
chosen at a distance of 1.5–2 DD away from the margins 
of the ONH. Baseline diameters of both the artery and 
vein were recorded according to the standard RVA proto-
col [26] for 50 s and then followed by three cycles of 20 s 
flicker provocation with each 80 s recovery time. Result-
ing in a 350 s measuring period during which the fellow 
eye was occluded to improve patient fixation. From these 
diameter recordings of arteries and veins the values for 
baseline diameter fluctuation (BDF) maximum dilation 
(MD), maximum constriction (MC) and dilation ampli-
tude (DA), time to reach MD following flickering light 
initiation (reaction time, RT) and arterial constriction 
time (CT = time to reach MC) were calculated for single 
flicker cycles and averaged responses [27].
Area under the curve parameters of retinal arteriolar 
responses to FL were calculated using the averaged time 
course of all three FL cycles.  AUCBaseline: area under the 
curve of the averaged 30 s prior to flicker start,  AUC20 s 
FL: area under the curve of the averaged profile during 
20 s flicker [28],  AUC20 s Constriction: area under the curve 
of 20  s duration 10  s following flicker cessation and 
 AUCLast 30 s: area under the curve of the last 30 s of the 
averaged reaction profile [29] (see Fig. 2).
Statistical analysis
We tested the hypothesis that levels of a test statistic 
with a mean of 100 arbitrary units (standard deviation 
14  units) would differ by 10% in patients with diabetes 
and cardiovascular disease compared with those patients 
with diabetes alone or cardiovascular disease alone. To 
achieve this at alpha  <0.01 and 1-beta  =  0.80 calls for 
data from 36 subjects per group. We therefore recruited 
consecutive patients until this sample size was achieved 
in each group. Associations between continuously-var-
iable factors were sought using Spearman’s correlation. 
With this sample size per group, risks of types 1 and 2 
statistical error are minimised when a correlation coeffi-
cient (r) exceeds 0.5.
Cross-sectional differences between the three groups 
were assessed using analysis of variance or the Kruskal–
Wallis test, depending on distribution. Categorical data 
was analysed by the Chi squared test. Between group dif-
ferences were sought using Tukey’s post hoc test. Prior 
to averaging retinal vessel responses of the three flicker 
cycles, within group analyses of the three flicker light 
cycles were sought using Friedman’s repeated (two-way) 
measures ANOVA. Comparisons between software gen-
erated dilatory parameters (the software generates three 
arterial parameters from averaged flicker responses 
 [Amax,  Amin and  Apeak] and one venous response  [Vmax]) 
and sequential diameter response analyses (SDRA) [27] 
were sought by paired t test whereas subgroup analy-
ses of patients with diabetic retinopathy were compared 
using the Mann–Whitney-U test or t test (supplemen-
tary data). Statistical significance was set at p < 0.05, and 
Table 1 Clinical data, medication and demographics
Data presented as mean with standard deviation, or as number of subjects and 
percentage
CA caucasian, SA South Asian, B black, M male, f female, SBP systolic blood 
pressure, DBP diastolic blood pressure, HR heart rate, IOP intraocular pressure, 
BMI body mass index, HbA1C glycated haemoglobin, DM diabetes mellitus, 
ACEI angiotensin-converting-enzyme inhibitor, ARB angiotensin receptor 
blockers, DPP-4 dipeptidyl peptidase-4 (‘gliptins’), GLP-1 glucagon-like peptide-1 
(exenatide, liraglutide)
* Different compared to the two other groups (p < 0.01)
+  Different to the CVD group (p < 0.01)
DM (n = 36) CVD (n = 43) DM and CVD 
(n = 37)
DM type: 1/2 2/34 – 1/36
Ethnicity: CA/SA/B 28/4/4 37/4/2 32/5/0
Age (years) 64 (10) 64 (11) 65 (9)
Gender (m/f ) 24/12 30/13 32/5
SBP (mmHg) 130 (13) 125 (19) 125 (16)
DBP (mmHg) 75 (9) 75 (13) 67 (10)*
HR (beats per 
minute)
76 (14) 67 (11)* 72 (16)
IOP (mmHg) 15 (3)+ 13 (2) 14 (2)
BMI (kg/m2) 31 (6) 27 (4)* 31 (6)
HbA1c (mmol/mol) 58 (15) 42 (3)* 61 (20)
DM duration (years) 11 (4.5–16) – 10 (4–17)
Medications
 Calcium channel 
blocker
20, 56% 13, 30% 14, 38%
 ACEI/ARB 23, 64% 31, 72% 30, 81%
 Metformin 26, 72% – 21, 57%
 Sulphonylurea 7, 19% – 7, 19%
 DPP-4 inhibitor 8, 22% – 6, 16%
 Insulin 15, 42% – 14, 38%
 GLP-1 agonist 4, 11% – 4, 11%
 Piaglitazone 4, 11% 2, 5%
 Lipid-lowering 26, 72% 41, 95% 36, 97%
 Aspirin 11, 31% 35, 81% 30, 81%
 Clopidogrel 1, 3% 7, 16% 7, 19%
 Nitrate – 11, 26% 11, 30%
 Oral anticoagulant 6, 17% 5, 12% 5, 14%
 Beta-blocker 10, 28% 19, 44% 22, 59%
 Diuretic 18, 50% 9, 21% 18, 49%
 Thyroxine 6, 17% 6, 14% 3, 8%
Cardiovascular disease
 Coronary artery 
disease
– 31, 72% 30, 81%
 Peripheral artery 
disease
– 5, 12% 4, 11%
 Cerebrovascular 
disease
– 8, 19% 3, 8%
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results are reported as either mean (standard deviation) 
or as median (upper quartile-lower quartile). All data 
were analysed using Statistica Version 12.4 (Dell Soft-
ware, Dublin, Ireland).
Results
Table 1 shows clinical, demographic, medication and co-
morbidity details of the 116 patients (36 DM only [2 Type 
1 and 34 Type 2], 43 CVD only and 37 CVD and DM [1 
Type 1 and 36 Type 2]). The three groups were matched 
for age (ANOVA p  =  0.769) and sex (X2 p  =  0.110). 
Patients with DM and CVD had lower DBP than the 
other two groups, whilst heart rate, HbA1c and body 
mass index were lower in those with CVD alone. There 
was no difference in the distribution of the type of CVD 
between the two groups with this disease (X2 p = 0.405). 
Table 2 shows retinal indices (summarized retinal vessel 
calibres and software generated vessel dynamic retinal 
vessel parameters). There were no significant differences 
between the three groups.
Table  3 and Fig.  3 shows the averaged dynamic retinal 
vessel diameter and responses to flicker light stimulation 
of both arteries and veins. In cross-sectional analyses, the 
arterial BDF was lower in DM only group compared to the 
other two groups. The DM + CVD groups’ arterial maxi-
mum constriction following flicker cessation was incon-
sistent throughout the three flicker provocations, with the 
second cycles’ response being the largest compared to the 
first and third (−1.79; −2.50 and −1.68%; p = 0.006), this 
was not the case for the other two groups. The average 
arterial MC however was lower in those with DM alone 
compared to the two other groups. In single flicker analy-
ses, the arterial RT was shortest in the second cycle than in 
the first and third cycles in the DM and CVD group only 
(20 s, 16 s, 23 s; p = 0.004). There were no such differences 
between individual flicker cycles in the other two groups. 
There was no difference between the three groups in 
regards of the venous responses to flicker light provo-
cation. Table  4 shows area under the curve data: this 
index confirmed the significantly lower arterial vessel 
Fig. 1 Sample image showing measurement area for static retinal vessel evaluation. Central ring denotes the diameter of the disc (1 DD), the 
second and third circle are each ½ DD separated to create a ½ DD wide concentric ring segment around the optic nerve head. This ring segment is 
highlighted here in yellow to illustrate the area in which retinal arterial and venous calibres are measured to calculate central retinal artery and vein 
equivalents (CRAE and CRVE)
Page 5 of 10Heitmar et al. Cardiovasc Diabetol  (2017) 16:56 
constriction in those with DM alone compared to the two 
other groups. The only significant correlation where the 
r value exceeded 0.45 was between the disease duration 
in patients with diabetes alone and the CRVE (r =  0.57, 
p < 0.001). Of the 73 patients with diabetes, six had dia-
betic retinopathy (according to UK DR  gradinga). With 
this small number, no analyses will be meaningful. Table 5 
shows serum endothelial markers. vWf was higher in 
DM  +  CVD than in the other two groups, whilst sEsel 
was high in patients with DM + CVD versus patients with 
DM alone. In the DM alone group, vWf correlated with 
the venous reaction time in the first flicker cycle (r = 0.5, 
p = 0.003). In the DM + CVD group, sEsel correlated with 
CRVE (r = 0.54, p = 0.004) and with the AVR (r = −0.62, 
p  =  0.001). There were no other statistically significant 
correlations.
Fig. 2 Schematic to illustrate area under the curve calculations. The highlighted areas in grey denote the time zones from which “Area under the 
curve” (AUC) data was calculated for baseline, during flicker, constriction and of the final 30 s
Table 2 Retinal parameters
Summarized retinal vessel calibres and software generated vessel reactivity parameters
Data presented as mean (SD) or median (lower quartile-upper quartile)
Au arbitrary units, CRAE central retinal artery equivalent, CRVE central retinal vein equivalent, AVR arterio-venous ratio, Amax IMEDOS software generated arterial 
maximum dilation to flicker, Amin IMEDOS software generated arterial maximum constriction following flicker, Apeak IMEDOS software generated arterial dilation 
amplitude, Vmax IMEDOS software generated venous maximum dilation to flicker
p values by analysis of variance or the Kruskal–Wallis test as distribution demands
DM (n = 36) CVD (n = 43) DM and CVD (n = 37) p value
CRAE (au) 178 (21) 175 (18) 175 (11) 0.660
CRVE (au) 213 (19) 208 (19) 215 (18) 0.212
AVR 0.84 (0.02) 0.85 (0.02) 0.83 (0.01) 0.389
Amax (%) 0.90 (0.45–2.45) 0.80 (−0.1 to 2.50) 0.90 (0.10–1.80) 0.558
Amin (%) −0.40 (−0.85 to 0.05) −0.50 (−1.10 to 0.20) −0.50 (−1.10 to 0.10) 0.905
Apeak (%) 1.55 (0.40–3.25) 1.60 (0.30–2.90) 1.20 (0.20–2.40) 0.662
Vmax (%) 3.25 (2.00–3.90) 3.10 (1.80–4.10) 2.50 (1.30–3.60) 0.206
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Discussion
We report several differences in retinal vessel physiology 
in those with DM alone, those with CVD alone, and those 
with both DM and CVD which confirm and extend those 
of others [16–18]. However, in our study, we found no 
differences in CRAE, CRVE, the AVR or IMEDOS indi-
ces in those with or without diabetes and/or cardiovas-
cular disease. The reason for this negative finding could 
be that early changes due to inflammation as described 
by Virchow’s triad are present in all three groups. These 
alterations of the vascular system affecting blood flow, 
contributing to hypercoagulability and inducing vessel 
wall alterations through endothelial injury all contribute 
to an altered vessel structure over time but may present 
first by a change in vessel physiology prior to signs of 
structural damage.
Nevertheless, we found multiple differences to the 
responses of arteries to flicker stimulation, the most 
marked being those of the arterial MC and RT. These 
shared the property that responses with a difference in 
the second cycle compared to the first and third cycles 
in those with both DM and CVD, providing evidence of 
differences in the time course of arterial vessel dynamics 
in these pathologies. Averaged vessel diameter responses 
(as calculated by the software of the RVA and referred 
to as IMEDOS values) can mask differences not only in 
regards to reaction patterns but also underestimate the 
overall dilatory capacity [27]. While all three groups 
showed comparable results for summarised retinal ves-
sel diameters and dynamic responses to flicker light 
patients suffering from DM alone exhibited increased 
vessel diameters (CRVE) with increased disease dura-
tion, confirming results of previous studies [30]. Further-
more, venous response to flicker light provocation was 
decreased with increasing disease duration. This decrease 
in venous dilation is in agreement with data described 
elsewhere [17, 18, 21, 30] and can be partly explained by 
the possibility that a pre-dilated vessel (as reflected by the 
increase in CRVE with increasing disease duration) has 
reduced residual dilatory capacity.
Area under the curve (AUC) analyses provides data 
that takes into account the time course as well as the 
extent of the vessel dilation recorded. The results of 
which confirm a lack of constriction in patients suf-
fering from DM only compared to both other groups. 
Our finding is supported by a recently published study 
from Lott and colleagues, who have shown an impaired 
coronary and retinal arterial (and venous) vasoconstric-
tor response in patients suffering from DM compared 
to controls [31]. While this was a much smaller sample 
and applied a different methodology using a hyperoxic 
vs our flicker light stimulus, it confirms our results of 
an impaired ability of DM only patients to constrict to a 
physiologic stimulus. Our results of the SDRA and AUC 
Table 3 Dynamic arterial and venous vessel parameters
Retinal vessel reactivity parameters as calculated using sequential diameter response analysis (SDRA)
Data presented as mean (standard deviation) or median (inter quartile range)
All values given in percentage change to baseline vessel diameters or times in seconds
BDF baseline diameter fluctuation, MD maximum dilation, MC maximum constriction, DA dilation amplitude, RT reaction time, CT constriction time, s seconds
p values by analysis of variance (ANOVA)
* Different compared to CVD group (p < 0.05)
** Different compared to CVD and DM group (p < 0.05)
DM (n = 36) CVD (n = 43) DM and CVD (n = 37) p value
Arterial parameters
 ASIZE (µm) 110 (16) 113 (20) 116 (18) 0.294
 BDF (%) 1.66 (0.81)* 2.59 (1.95) 2.38 (1.38) 0.019
 MD (%) 2.99 (2.23) 2.88 (2.29) 2.60 (1.68) 0.705
 MC (%) −1.45 (0.87)** −2.06 (1.50) −2.17 (1.52) 0.030
 RT (s) 18 (11) 20 (12) 20 (12) 0.679
 CT (s) 40 (10) 38 (8) 40 (7) 0.531
Venous parameters
 Vsize (µm) 141 (20) 141 (19) 142 (18) 0.927
 BDF (%) 1.91 (0.88) 2.53 (2.09) 2.45 (1.52) 0.192
 MD (%) 4.34 (1.85) 4.28 (1.96) 4.16 (2.24) 0.928
 MC (%) −0.80 (1.20) −0.79 (1.53) −0.72 (1.15) 0.963
 DA (%) 5.14 (2.25) 5.07 (2.22) 4.88 (2.64) 0.892
 RT (s) 21 (9) 20 (4) 21 (7) 0.972
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analysis confirm a physiological difference in flicker light 
induced vessel dilation in DM. While the changes of the 
vascular system are present in all three groups, they can 
manifest with differing severity and hence partly explain 
this difference in behaviour.
Further explanations for the differences between 
groups that may be found in the underlying mechanisms 
involved in regulating vascular reactivity to flicker light 
include nitric oxide synthase and bioavailability [32], 
endothelial function [14] and ganglion cell signalling [33]. 
Fig. 3 Averaged response to flicker light provocation of retinal vessels. Mean arterial (top graph) and retinal vein (bottom graph) responses for all 
three patient groups (black solid line DM only; grey solid line CVD; black dotted line DM and CVD)
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While NO synthase, NO bioavailability and endothelial 
health can be compromised in both DM and CVD, this 
is dependent upon disease duration as well as on medi-
cation. In this respect our finding of decreased arterial 
constriction following flicker light provocation in the DM 
only group is in agreement and expanding the data pub-
lished by others [17, 34]. One group [33] found that this 
lack of arterial vasoconstrictor capacity was attributed to 
an alteration of nitric oxide production and bioavailabil-
ity, whereas others [17] suggest that the overall reduced 
dilatory and constriction response could serve as an esti-
mate of endothelial cell capacity to respond to a physi-
ological stimulus. Furthermore, one study examining 
DM patients with varying severity of retinopathy demon-
strated ganglion cell death with increasing severity of the 
retinopathy [35]. Our finding of more adverse endothe-
lial markers in DM + CVD versus the other groups is in 
keeping with accepted pathophysiology [36, 37]. How-
ever, there were only three instances where levels of the 
markers correlated meaningfully with an ocular index, 
suggesting limited predictive value unless confirmed in a 
far larger population.
Some of the retinal parameters examined in the present 
study were comparable between the three groups. One 
explanation for this can be found in the fact that only 
six diabetic patients suffered from DR. Previous work 
examining retinal vessel calibres, carotid plaque and the 
impact of exercise on echocardiography parameters all 
confirmed that patients with DR compared to those suf-
fering from DM without DR or CVD only had a higher 
risk of adverse CVD events and impaired myocardial 
function [38–40]. These findings are somewhat unsur-
prising given that with increasing duration of DM (and 
age) the prevalence of DR is increasing too, which is 
reflecting disease progression and a compromised micro-
circulation which in turn leads to a higher risk of adverse 
CVD events. As the majority of the patients assessed 
in the present study is free from DR this might explain 
in part why there were only subtle differences across 
groups. Observations over time taking into considera-
tion DR onset will provide further insight into whether 
the differences in reaction pattern and the lack of arte-
rial constriction to flicker light provocation in DM only 
patients is changing over time.
We acknowledge the artificial nature of the three 
groups, in that it is very likely that many of those we con-
sider to have DM only will be carrying asymptomatic 
CVD. This also applies to the definition of DM, although 
we have strength in that our measurement of  HbA1c is 
robust and was performed on all subjects.
Conclusion
In summary, patients with DM exhibit different retinal 
vessel reactivity patterns to flicker light provocation com-
pared to those suffering from CVD only or a combination 
of both. While summarised (i.e. averaged across all flicker 
Table 4 AUC data
All data are presented as either means (± standard deviation) or median (upper quartile/lower quartile). Statistical significance is shown by bolded p-values. All values 
given in percentage change to baseline vessel diameters or times in seconds
AUCbaseline area under the curve of the averaged 30 s prior to flicker start, AUC20 s FL area under the curve of the averaged profile during 20 s flicker, AUC20s Constriction area 
under the curve of 20 s duration 10 s following flicker cessation, AUCLast 30s area under the curve of the last 30 s of the averaged reation profile
p value by analysis of variance or the Kruskal–Wallis test
* p < 0.05 lower than the two other groups
DM (n = 36) CVD (n = 43) DM and CVD (n = 37) p value
AUCBaseline data −0.9 (2.0) −1.4 (2.2) −1.0 (3.1) 0.704
AUC20 s Flicker 14.9 (6.0–30.1) 19.8 (−0.7–37.8) 12.0 (1.1–24.7) 0.429
AUC20 s Constriction −4.0 (−15.7 to 3.8)* −14.4 (−27.5 to −3.4) −10.1 (−20.0 to −3.7) 0.038
AUCLast 30 s −3.5 (18.9) −6.7 (26.0) −7.3 (23.1) 0.748
Table 5 Serum endothelial markers
Data mean (SD), p value from ANOVA
a  p = 0.004 to DM and CVD group
b  p = 0.02 to DM and CVD group
c  p = 0.044 to DM and CVD group (inter-group p values Tukey’s post hoc test)
DM (n = 36) CVD (n = 43) DM and CVD (n = 37) P value
Von Willebrand factor (IU/dL) 107 (21)a 111 (20)b 124 (22) 0.003
Soluble E selectin (ng/mL) 22 (8)c 26 (8) 27.5 (12) 0.03
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light cycles) retinal vessel diameters provide only limited 
capacity to distinguish between groups with different 
systemic vascular disease, dynamic vessel analysis using 
SDRA can do so if individual flicker light cycle patterns 
are analysed. Averaged retinal responses to flicker light 
lack the capacity to examine a change in reaction pat-
tern and can mask changes in the reaction pattern. We 
note that only data with three complete cycle recordings 
should be used for average calculations as it would other-
wise potentially distort the dilatory response especially in 
cases where there are differences between flicker cycles, 
such as demonstrated in our sample. Future research is 
needed to establish if retinal vessel reaction patterns 
change over time or with increased cardiovascular risk 
factors.
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